Cogstate (ASX:CGS) has released a business update for the third quarter ended March 31.
The company continues to capitalise on robust global demand for central nervous system indications, reporting a surge in sales contracts that reinforces its dominant position in the healthcare technology sector.
During Q3, Cogstate executed sales contracts totalling US$25.4 million, representing a staggering 263% increase compared to the US$7.01 million recorded in the same period last year.
The quarterly performance has propelled the total value of executed contracts for the first nine months of the 2026 financial year to US$67.1 million.
To put this trajectory into perspective, the total for the same nine-month period in FY25 was US$27.31 million and only US$18.72 million in FY24, highlighting an extraordinary period of accelerated commercial momentum.
The influx of new contracts has substantially bolstered the company’s revenue outlook.
Contracted revenue for the second half of 2026 has climbed to US$29.1 million, up from the US$21.7 million projected at the end of December.
Consequently, the full-year FY26 revenue under contract now stands at US$56 million, surpassing the total revenue achieved in the entirety of FY25.
Looking further ahead, the company’s forward pipeline remains healthy, with contracted revenue for FY27 already reaching US$35.6 million.